1
|
Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, Wang G, Inigo I, Surguladze D, Pennello AL, Persaud K, Hindi S, Topper M, Chen X, Zhang Y, Bulaon DK, Bailey T, Lao Y, Han B, Torgerson S, Chin D, Sonyi A, Haidar JN, Novosiadly RD, Moxham CM, Plowman GD, Ludwig DL, Kalos M. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunol Res 2020; 8:1300-1310. [PMID: 32873605 DOI: 10.1158/2326-6066.cir-20-0304] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 06/03/2020] [Accepted: 07/24/2020] [Indexed: 11/16/2022]
Abstract
The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell-mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced antitumor activity, compared with monospecific PD-1 and PD-L1 antibodies. Here, we describe LY3434172, a bispecific IgG1 mAb with ablated Fc immune effector function that targets both human PD-1 and PD-L1. LY3434172 fully inhibited the major inhibitory receptor-ligand interactions in the PD-1 pathway. LY3434172 enhanced functional activation of T cells in vitro compared with the parent anti-PD-1 and anti-PD-L1 antibody combination or respective monotherapies. In mouse tumor models reconstituted with human immune cells, LY3434172 therapy induced dramatic and potent antitumor activity compared with each parent antibody or their combination. Collectively, these results demonstrated the enhanced immunomodulatory (immune blockade) properties of LY3434172, which improved antitumor immune response in preclinical studies, thus supporting its evaluation as a novel bispecific cancer immunotherapy.
Collapse
Affiliation(s)
- Helen Kotanides
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York.
| | - Yiwen Li
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Maria Malabunga
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Carmine Carpenito
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Scott W Eastman
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Yang Shen
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - George Wang
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Ivan Inigo
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - David Surguladze
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | | | | | - Sagit Hindi
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Michael Topper
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Xinlei Chen
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Yiwei Zhang
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Danielle K Bulaon
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Tim Bailey
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Yanbin Lao
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Bing Han
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Stacy Torgerson
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Darin Chin
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Andreas Sonyi
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Jaafar N Haidar
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | | | | | - Gregory D Plowman
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Dale L Ludwig
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Michael Kalos
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York.
| |
Collapse
|
2
|
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J Immunother Cancer 2018; 6:45. [PMID: 29866166 PMCID: PMC5987621 DOI: 10.1186/s40425-018-0354-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Accepted: 05/14/2018] [Indexed: 11/10/2022] Open
Affiliation(s)
- Yiwen Li
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA. .,Eli Lilly and Company, 450 East 29th Street, New York, NY, 10016, USA.
| | - Carmine Carpenito
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - George Wang
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - David Surguladze
- Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, NY, USA
| | - Amelie Forest
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Maria Malabunga
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Mary Murphy
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Yiwei Zhang
- Lilly Research Laboratories, Department of Biologics Technology, New York, NY, USA
| | - Andreas Sonyi
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Darin Chin
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Douglas Burtrum
- Lilly Research Laboratories, Department of Biologics Technology, New York, NY, USA
| | - Ivan Inigo
- Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, NY, USA
| | - Anthony Pennello
- Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, NY, USA
| | - Leyi Shen
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Laurent Malherbe
- Lilly Research Laboratories, Department of Non-Clinical Safety, Indianapolis, IN, USA
| | - Xinlei Chen
- Lilly Research Laboratories, Department of Quantitative Biology, New York, NY, USA
| | - Gerald Hall
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Jaafar N Haidar
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Dale L Ludwig
- Lilly Research Laboratories, Department of Biologics Technology, New York, NY, USA
| | - Ruslan D Novosiadly
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Michael Kalos
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA. .,Eli Lilly and Company, 450 East 29th Street, New York, NY, 10016, USA. .,Janssen Pharmaceutical Companies of Johnson and Johnson, Springhouse, PA, USA.
| |
Collapse
|
3
|
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J Immunother Cancer 2018; 6:31. [PMID: 29712568 PMCID: PMC5925824 DOI: 10.1186/s40425-018-0329-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 02/20/2018] [Indexed: 12/25/2022] Open
Abstract
Background Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity, leading to durable objective responses in a subset of patients across multiple tumor types. Results Here we describe the discovery and preclinical characterization of LY3300054, a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors PD-1 and CD80. The functional activity of LY3300054 on primary human T cells is evaluated using a series of in vitro T cell functional assays and in vivo models using human-immune reconstituted mice. LY3300054 is shown to induce primary T cell activation in vitro, increase T cell activation in combination with anti-CTLA4 antibody, and to potently enhance anti-tumor alloreactivity in several xenograft mouse tumor models with reconstituted human immune cells. High-content molecular analysis of tumor and peripheral tissues from animals treated with LY3300054 reveals distinct adaptive immune activation signatures, and also previously not described modulation of innate immune pathways. Conclusions LY3300054 is currently being evaluated in phase I clinical trials for oncology indications. Electronic supplementary material The online version of this article (10.1186/s40425-018-0329-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yiwen Li
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA .,0000 0000 2220 2544grid.417540.3Eli Lilly and Company 450 East 29th Street 10016 New York NY USA
| | - Carmine Carpenito
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - George Wang
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - David Surguladze
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Preclinical Pharmacology New York NY USA
| | - Amelie Forest
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Maria Malabunga
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Mary Murphy
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Yiwei Zhang
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA
| | - Andreas Sonyi
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Darin Chin
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Douglas Burtrum
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA
| | - Ivan Inigo
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Preclinical Pharmacology New York NY USA
| | - Anthony Pennello
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Preclinical Pharmacology New York NY USA
| | - Leyi Shen
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Laurent Malherbe
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Non-Clinical Safety Indianapolis IN USA
| | - Xinlei Chen
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Quantitative Biology New York NY USA
| | - Gerald Hall
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Jaafar N Haidar
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Dale L Ludwig
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA
| | - Ruslan D Novosiadly
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Michael Kalos
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA .,0000 0000 2220 2544grid.417540.3Eli Lilly and Company 450 East 29th Street 10016 New York NY USA.,grid.430674.2Janssen Pharmaceutical Companies of Johnson and Johnson Springhouse PA USA
| |
Collapse
|
4
|
Yin Y, Ren X, Smith C, Guo Q, Malabunga M, Guernah I, Zhang Y, Shen J, Sun H, Chehab N, Loizos N, Ludwig DL, Ornitz DM. Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody. Dis Model Mech 2016; 9:563-71. [PMID: 27056048 PMCID: PMC4892666 DOI: 10.1242/dmm.024760] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2016] [Accepted: 03/30/2016] [Indexed: 12/20/2022] Open
Abstract
Activating mutations in fibroblast growth factor receptor 3 (FGFR3) have been identified in multiple types of human cancer and in congenital birth defects. In human lung cancer, fibroblast growth factor 9 (FGF9), a high-affinity ligand for FGFR3, is overexpressed in 10% of primary resected non-small cell lung cancer (NSCLC) specimens. Furthermore, in a mouse model where FGF9 can be induced in lung epithelial cells, epithelial proliferation and ensuing tumorigenesis is dependent on FGFR3. To develop new customized therapies for cancers that are dependent on FGFR3 activation, we have used this mouse model to evaluate a human monoclonal antibody (D11) with specificity for the extracellular ligand-binding domain of FGFR3, that recognizes both human and mouse forms of the receptor. Here, we show that D11 effectively inhibits signaling through FGFR3 in vitro, inhibits the growth of FGFR3-dependent FGF9-induced lung adenocarcinoma in mice, and reduces tumor-associated morbidity. Given the potency of FGF9 in this mouse model and the absolute requirement for signaling through FGFR3, this study validates the D11 antibody as a potentially useful and effective reagent for treating human cancers or other pathologies that are dependent on activation of FGFR3. Summary: This study validates the FGF9 lung adenocarcinoma mouse model as a tool to screen and evaluate potential therapeutics that are designed to inhibit FGF9 or its target receptor, FGFR3.
Collapse
Affiliation(s)
- Yongjun Yin
- Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Xiaodi Ren
- Department of Quantitative Biology, Eli Lilly and Company, New York, NY 10016, USA
| | - Craig Smith
- Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Qianxu Guo
- Department of Cancer Angiogenesis, Eli Lilly and Company, New York, NY 10016, USA
| | - Maria Malabunga
- Department of Immunology, Eli Lilly and Company, New York, NY 10016, USA
| | - Ilhem Guernah
- Department of Immunology, Eli Lilly and Company, New York, NY 10016, USA
| | - Yiwei Zhang
- Department of Antibody Technology, Eli Lilly and Company, New York, NY 10016, USA
| | - Juqun Shen
- Department of Antibody Technology, Eli Lilly and Company, New York, NY 10016, USA
| | - Haijun Sun
- Department of Bioprocess Sciences, Eli Lilly and Company, New York, NY 10016, USA
| | - Nabil Chehab
- Department of Immunology, Eli Lilly and Company, New York, NY 10016, USA
| | - Nick Loizos
- Department of Immunology, Eli Lilly and Company, New York, NY 10016, USA
| | - Dale L Ludwig
- Department of Bioprocess Sciences, Eli Lilly and Company, New York, NY 10016, USA
| | - David M Ornitz
- Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO 63110, USA
| |
Collapse
|
5
|
Wang W, Cheng Y, Deevi D, Li H, Prewett M, Bassi R, Malabunga M, Paz K, Sun H, Tonra J. 200 POSTER Transcriptome analysis method for in vivo mechanism of action study: IMC-D11 anti-FGFR3 +/− cisplatin in bladder cancer models. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72132-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H, Berthoud HR, McGuinness OP, Shen J, Bohlen P, Leibel RL, Kussie P. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 2007; 292:E964-76. [PMID: 17132826 DOI: 10.1152/ajpendo.00089.2006] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
We generated three fully human monoclonal antibody antagonists against fibroblast growth factor receptor-1 (FGFR1) that potently block FGF signaling. We found that antibodies targeting the c-splice form of the receptor (FGFR1c) were anorexigenic when administered intraperitoneally three times weekly to mice, resulting in rapid, dose-dependent weight loss that plateaued (for doses>4 mg/kg) at 35-40% in 2 wk. Animals appeared healthy during treatment and regained their normal body weights and growth trajectories upon clearance of the antibodies from the bloodstream. Measurements of food consumption and energy expenditure indicated that the rapid weight loss was induced primarily by decreased energy intake and not by increased energy expenditure or cachexia and was accompanied by a greater reduction in fat than lean body mass. Hypophagia was not caused through malaise or illness, as indicated by absence of conditioned taste aversion, pica behavior, and decreased need-induced salt intake in rats. In support of a hypothalamic site of action, we found that, after intraperitoneal injections, anti-FGFR1c (IMC-A1), but not a control antibody, accumulated in the median eminence and adjacent mediobasal hypothalamus and that FGFR1c is enriched in the hypothalamus of mice. Furthermore, a single intracerebroventricular administration of 3 microg of IMC-A1 via the 3rd ventricle to mice caused an approximately 36% reduction in food intake and an approximately 6% weight loss within the ensuing 24 h. Our data suggest that FGF signaling through FGFR1c may play a physiological role in hypothalamic feeding circuit and that blocking it leads to hypophagia and weight loss.
Collapse
Affiliation(s)
- Haijun D Sun
- ImClone Systems Inc., 180 Varick St., New York, NY 10014, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|